Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company provides cough and phlegm, kidney, anti-infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, res… Read more
Teyi Pharmaceutical Group Co Ltd (002728) - Total Liabilities
Latest total liabilities as of September 2025: CN¥417.67 Million CNY
Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) has total liabilities worth CN¥417.67 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Teyi Pharmaceutical Group Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Teyi Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Teyi Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | ₹2.75 Billion |
|
Tinexta S.p.A.
LSE:0RIW
|
UK | €633.49 Million |
|
Investis Holding SA
SW:IREN
|
Switzerland | CHF839.14 Million |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥9.78 Billion |
|
Chongqing Shunbo Aluminum Co Ltd
SHE:002996
|
China | CN¥11.89 Billion |
|
The Hongkong and Shanghai Hotels Limited
F:HSG
|
Germany | €20.39 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Teyi Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Teyi Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Teyi Pharmaceutical Group Co Ltd (2009–2024)
The table below shows the annual total liabilities of Teyi Pharmaceutical Group Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥635.94 Million | +26.69% |
| 2023-12-31 | CN¥501.95 Million | -56.06% |
| 2022-12-31 | CN¥1.14 Billion | +42.01% |
| 2021-12-31 | CN¥804.51 Million | -31.57% |
| 2020-12-31 | CN¥1.18 Billion | +6.52% |
| 2019-12-31 | CN¥1.10 Billion | +15.41% |
| 2018-12-31 | CN¥956.39 Million | +7.93% |
| 2017-12-31 | CN¥886.14 Million | +23.66% |
| 2016-12-31 | CN¥716.61 Million | -9.72% |
| 2015-12-31 | CN¥793.78 Million | +782.35% |
| 2014-12-31 | CN¥89.96 Million | -13.00% |
| 2013-12-31 | CN¥103.40 Million | +0.50% |
| 2012-12-31 | CN¥102.88 Million | +78.29% |
| 2011-12-31 | CN¥57.71 Million | -29.56% |
| 2010-12-31 | CN¥81.92 Million | -5.26% |
| 2009-12-31 | CN¥86.47 Million | -- |